SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage ...

Ph.D., Nura Bio CEO. "We are delighted to have Lahar and Scott join our team as we enter the company’s next phase of expansion and clinical development. They will both play critical roles as we ...

Ph.D., Nura Bio CEO. “We are delighted to have Lahar and Scott join our team as we enter the company’s next phase of expansion and clinical development. They will both play critical roles as ...

“At Nura Bio, we have made significant progress in developing our company and pipeline,” said Shilpa Sambashivan, Ph.D., Nura Bio CEO. “We are delighted to have Lahar and Scott join our team as we ...

“We are thrilled to welcome both Jay and Faraz to our leadership team,” said Timothy Lu, M.D., Ph.D, CEO of Senti Bio. “Jay has a track record of financial excellence, industry experience ...

"We are pleased to welcome Chris to the team. He is a versatile and experienced industry professional whose expertise ... in western Scotland and Ireland—challenges we believe our technology can help ...

Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes ...

Nura Bio, Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, announced today ...

The company returned to the grid as a title sponsor in 2018. In 2019 the team would make an official return to the grid as a constructor as Sauber would be renamed as Alfa Romeo Racing.

(Nasdaq: SNTI) ("Senti Bio” or the "Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced an ...